Summit Therapeutics plc, the drug discovery and development company advancing therapies for rare diseases and infectious diseases, announces that it will present at the Biotech Showcase(TM), taking place 8-10 January in San Francisco, CA, US. The presentation will take place today, 9 January, at 4:00pm PST.

A live audio webcast of the presentation will be available through the Investors section on the Company's website, www.summitplc.com. A replay of the webcast will be available from the same location soon after the live presentation.

About Summit Therapeutics

Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit

 

 

Glyn Edwards / Richard Pye (UK office)

Tel:

44 (0)1235 443 951

Erik Ostrowski / Michelle Avery (US office)

 

+1 617 225 4455

 

 

 

Cairn Financial Advisers LLP (Nominated Adviser)

Tel:

+44 (0)20 7213 0880

Liam Murray / Tony Rawlinson

 

 

 

 

 

N+1 Singer (Joint Broker)

Tel:

+44 (0)20 7496 3000

Aubrey Powell / Jen Boorer

 

 

 

 

 

Panmure Gordon (Joint Broker)

Tel:

+44 (0)20 7886 2500

Freddy Crossley / Duncan Monteith, Corporate Finance

 

 

Tom Salvesen, Corporate Broking

 

 

 

 

 

MacDougall Biomedical Communications (US)

Tel:

+1 781 235 3060

Karen Sharma

 

ksharma@macbiocom.com

 

 

 

Consilium Strategic Communications (UK)

Tel:

+44 (0)20 3709 5700

Mary-Jane Elliott / Sue Stuart /

 

summit@consilium-comms.com

Jessica Hodgson / Philippa Gardner

 

 


-END-